tislelizumab
Tevimbra Approved for Some Patients With Unresectable or Metastatic ESCC
The FDA has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for ...
MARCH 4, 2025
Tislelizumab Vies for First-Line Designation in Treatment of Advanced HCC
The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma ...
NOVEMBER 20, 2023
Load more